

DAFTAR PUSTAKA

1. Azis MF. Masalah kanker serviks di Indonesia. Dalam : Pelatihan tes pap dan IVA. Pra PIT XII POGI. Palembang 2001.
2. Sirait AM. Ketahanan hidup penderita kanker serviks di Rumah Sakit Dr. Cipto Mangunkusumo Jakarta. MOGI 1997;13: 182-88.
3. Rock JA, Thompson JD. Invasive carcinoma of the cervix. In : Te Linde's Operative Gynecology 8th ed. Philadelphia: J.B. Lippincott Company; 1997.p.1413-99.
4. Mackey EV, Khoo SK, Daunter B. Tumor marker. In :Coppleson M. ed. Gynecologic oncology, fundamental principles and clinical practice. London: Churchill Livingstone; 1991.p.270-82.
5. Holschneider CH. Premalignant and malignant disorders of the uterine cervix. In: Current Obstetrics and Gynecologic, 9th ed. Boston 2003.p.894-908.
6. Bischer A, Giegerl E. Tumor marker in cervical carcinoma. Clinical Consultations in Obstetric and Gynecology 1995.p. 7:94-100.
7. Magdelenat H, Fenton J, Ouhajjou A. Radioimmunoassay of SCC Antigen in Squamous Cell Carcinoma of the Uterine Cervix. Excerpta Medica, 1997.p.71-4.
8. Ngan HY, Chan SY, Wong LC, Choy DT, Ma HK. Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervix. Gynecol Oncol. 1990;37(2):260-3.
9. Hong JH, Tsai CS, Chang JT, Wang CC, Lai CH, Lee SP, et al. The prognostic significance of pre-and posttreatment SCC level in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys, 1998 Jul;41(4):823-30.
10. Micke O, Prott FJ, Schafer U, Tangerding S, Potter R, Willich N. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res, 2000;20(6D):5113-5. Available from URL :<http://www.wccenter.com/cervix.html>
11. Ohno T, Nakayama Y, Nakamoto S, Kato S, Imai R, Nonaka T, et al. Measurement of serum squamous cell carcinoma antigen level as predictor of radiation response in patients with carcinoma of the uterine cervix. Cancer, 2003 Jun;97(12):3114-20.
12. Iskandar TM, Suprijono. Peran squamous cell carcinoma (SCC) dalam evaluasi keberhasilan terapi karsinoma serviks uteri. Dalam : Naskah lengkap KOGI Palembang, 2001.
13. Sjamsuddin S. Prinsip-prinsip dasar kanker serviks. Kumpulan makalah Subbagian Onkologi Bagian Obstetri dan Ginekologi FKUI/RSCM, 1996.
14. National Cancer Institute-PDQ[®] Treatment health professionals. Cervical cancer. 2002. [cited July 16, 2003]. Available from : http://www.meds.com/pdq/cervical_pro.html

15. Zarofin T. Ketahanan hidup kanker serviks tahun 1988 di RSCM Jakarta. Tugas akhir pendidikan mahir onkologi ginekologi; Jakarta 1998.
16. Hidayat ST, Suyono B. Karakteristik kasus rujukan keganasan ginekologi di RS Dr. Kariadi. Dalam : Naskah lengkap PIT X POGI Ujung Pandang, 1997.p.140-42.
17. Iwasaka T, Oh-unchida M, Marsuo N, Yokoyama M, Fufuda K, Hara K, et al. Correlation between HPV positivity and state of the p53 gene in cervical carcinoma of cell lines. *Gynecol Oncol* 1993;p.104-9.
18. Southern SA, Herrington CS. Disruption of cell cycle control by human papilloma viruse with special reference to cervical carcinoma. *Int J Gynecol Cancer* 2000; 10:263-74.
19. Kitano Y, Fujisaki S, Nakamura N, Miyasaki K, Katsuki T, Okamura H. Immunological disorder against the Epstein-Barr virus infection and prognosis in patients with cervical carcinoma. *Gynecol Oncol* 1995,57 :150-7.
20. Andrijono. Kanker serviks. Dalam : Sinopsis Kanker Ginekologi. Badan Penerbit FKUI Edisi pertama, Jakarta 2003.p.14-35.
21. Armstrong BK, Munoz N, Bosch FX. Epidemiology of cancer of the cervix. In : Copleston M. 2nd ed. *Gynecologic Oncology*. New York: Churchill Livingstone; 1992.p.11-26.
22. Albert B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. *Molecular biology of the cell*. 3rd ed. Garland Publishing, Inc, New York & London ; 1994.p.950-99.
23. Abbas AK, Litchman AH, Pober JS, editors. *Immunity to tumors*. In : *Cellular and molecular immunology*. 3rd ed. Philadelphia : Saunders ; 1997.p.382-405.
24. Fingert HJ, Pardee BA, Campisi J. *Molecular biology and biochemistry of cancer*. In : Knapp J, Berkowitz RS, editors. *Gynecologic oncology*. 2nd ed. Boston : McGraw-Hill ; 1993.p.3-35.
25. DiSaia PJ, Creasman WT, editors. *Invasive cervical cancer*. In : *Clinical gynecologic oncology* 5th ed. St Louis: Mosby; 1997.p. 51-66.
26. Davis MA. Cervical neoplasia. [cited May 16, 2003]. Available from: http://www.medicallibrary.org/journals/secure/obgyn_review_p/secure/cervicalNeoplasia.htm.
27. Diagnosis and treatment of cervical carcinoma. In : *ACOG Practise Bulletin*;35. *Obstet Gynecol* 2002;99(1): 855-67.
28. Krivak TC. Cervical and vaginal cancer. In : *Novak's Gynecology* 13th ed. Philadelphia, USA: Lippincott William and Wilkin, 2002.p. 1199-211.
29. Malpica A. Pathology of cervical cancer. *Clinical Consultation in Obstetric and Gynecology*, 1995; 7:101-10.
30. World Health Organization. *International Histological Classification of tumours* 2nd ed. Histological typing of female genital tract tumours. Geneva, 1994: 41-54.
31. Benedet JL, Bender H, Jones III H, Ngan HYS, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancer. *Int J Gynecol Obstet* 2000; 70(2):209-62.
32. Eifel PJ. Radiation therapy. In: Berek JS, Hacker NF, editors. *Practical gynecologic oncology* 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2000.p. 117-58.

33. Argadikoesoema SG. Faktor prediksi respons radiasi pada karsinoma nasofaring [Disertasi] Program Pascasarjana Universitas Indonesia, 1998.
34. Hill RP. Cellular basis of radiotherapy. In : Tannock IF., Hill RP. Eds. The basic science of oncology. New York. Mc. Graw-Hill. Inc. Health professions Division, 1992.p.259-75.
35. Millan TJM, Steel GG. Molecular aspects of radiation biology. In:Steel GG.,eds. Basic clinical radiobiology. London: Edward Arnold, 1993.p.211-24.
36. Dowd Sb. Introduction of biologic effects: from cells to organs. In: Dowd SB.,eds. Practical radiation protection and applied radiobiology. Philadelphia: W.B. Saunders Company, 1994.p.67-85.
37. Belli JA. The radiobiologic basis for radiation therapy. In: Knapp RC, Berkowitz RS, eds. Gynaecologic Oncology. 2nd ed. Singapore, McGraw Hill Inc; 1993.p. 109-18.
38. Iskandar TM. Efektivitas linear accelerator pada pengobatan karsinoma serviks uteri. Semarang: Bagian Obstetri dan Ginekologi Fakultas Kedokteran Universitas Diponegoro,1996,100 pp. Thesis.
39. Feldmier JJ. Radiation oncology. In : Weiss GR, ed. Clinical Oncology. London, Prentice Hall International Inc; 1993.p.74-88.
40. Shingleton HM, Orr JW. Cancer of the cervix. Philadelphia : J.B. Lippincott Company, 1995.
41. Perhimpunan Onkologi Radiasi Indonesia (PORI). Standar pelayanan profesi radioterapi kanker leher rahim, 2000.
42. Moore M. Tumor immunology. In: Irvine WJ. editor. Medical immunology. Edinburgh : T Viot Scientific Publications, 1998.p.425-63.
43. Hilders CG, Munoz IM, Nooyen Y, Fleuren GJ. Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol 1995;57:366-75.
44. Sarjadi. Neoplasma I : vulva, vagina serviks dan korpus uteri. Dalam : Patologi ginekologi. Cetakan ke 2. Jakarta: Hipokrates; 1995.p.34-111.
45. Chan DW, Sell S. Tumor markers. In: Burtis CA, Ashwood ER, Aldrich JE. Eds. Tietz Fundamentals of Clinical Chemistry. 4th ed. Philadelphia: WB Saunders, 1996.p.336-50.
46. Lisyani S. Pengertian umum petanda tumor. Dalam: Seminar Petanda Tumor dalam Pengelolaan Onkologi. Badan Penerbit Universitas Diponegoro, Semarang 1997.p.9-19.
47. Kresno SB. Petanda tumor. Dalam: Imunologi : Diagnosis dan Prosedur Laboratorium. Badan Penerbit Fakultas Kedokteran Universitas Indonesia, Jakarta 2001.p.378-404.
48. Santoso RI. Penentuan kadar petanda ganas. Dalam : Seminar sehari Manfaat Pemeriksaan Tumor Marker. Jakarta, 1999.
49. Sutoto. Petanda tumor ginekologi. Dalam : Seminar Petanda Tumor Dalam Pengelolaan Onkologi. Badan Penerbit Universitas Diponegoro, Semarang 1997.p. 28-9.

50. Silverman GA, Jockel JI, Domer PH, Mohr RM, Taillon-Miller P, Korsmeyer SJ. Yeast artificial chromosome cloning of a two-megabase-sizecontig within chromosomal band 18q21 establishes physical linkagebetween BCL2 and plasminogen activator inhibitor type-2. *Genomics* 1991; 9:219-28.
51. Kuwano A, Kondo I, Kishi F. Assignment of the squamous cell carcinoma antigen locus (SCC) to 18q21 by in situ hybridization. *Genomics* 1995; 30 (3): 626.
52. Fujimoto J, Sakaguchi H, Aoki I, Tamaya T. The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers. *Cancer Research* 2000 Jul;60:3662-5. Available from URL :<http://www.cancerres.aacrjournals.org/cgi/..&FIRSTINDEX=25%26resourcetype>.
53. Cervical carcinoma : squamous cell carcinoma antigen. Available from URL :http://www.obstetrics.specialtylabs.com/books/print_view.asp?id=545-10k
54. Einarsson R. Squamous cell carcinoma antigen (SCCA) isomers-markers for squamous cell carcinoma. *Adv Clin Exp Med* 2005;14:643-8.
55. Suminami Y, Nagashima S, Murakami A, Nwata S, Gondo T, Hirakawa H, et al. Supression of a squamous cell carcinoma (SCC)-related Serpin, SSC antigen, inhibits tumor growth with increased intratumor infiltration of natural killer cells. *Cancer Res* 2001; 61:1776-80.
56. Kusumaningrum R. Hubungan persistensi DNA Virus Humanpapilloma dengan respon radiasi histopatologis pada penderita karsinoma serviks utero stadium lanjut yang telah mendapat terapi radiasi atau kemoradiasi. Semarang: Bagian Obstetri dan Ginekologi Fakultas Kedokteran Universitas Diponegoro, 2005, 75 pp. Thesis.
57. Taneja A, Rajaram S, Agarwal S, Singh KC, Sahni S, Goei N. “Quick Cycle” neoadjuvant chemotherapy in squamous cell carcinoma of cervix. *Indian J Pharmacol* 2005;37:320-4.
58. Ohara K, Tanaka YO, Tsunoda H, Nishida M, Sugahara S, Itai Y. Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging. *Obstet Gynaecol* 2002; 100:781-7.
59. Liu SS, Leung RC, Chan KY, Chiu P, Cheung AN, Tam K, et al. p73 Expression Is Associated with the Cellular Radiosensitivity in Cervical Cancer after Radiotherapy. *Clin Cancer Res* 2004;10: 3309-16
60. Dueñas-González A, Lizano M, Candelaria M, Cetina L, Arce C, Cervera E. Epigenetics of cervical cancer. An overview and therapeutic perspectives. *Mol Cancer* 2005;4:38.
61. Gaarenstroom KN, Bonfrer JMG. National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Cervical Cancer. NACB: Practice Guidelines And Recommendations For Use Of Tumor Markers In The Clinic – Cervical Cancer Manuscript (3J). Available from: http://www.nacb.org/Impg/tumor/chp3j_cervical.pdf. Accessed on 13 February 2006.
62. Esajas MD, Duk JM, de Bruijn HWA, Aalders JG, Willemse PHB, Sluiter W, et al. Clinical Value of Routine Serum Squamous Cell Carcinoma Antigen in

- Follow-Up of Patients With Early-Stage Cervical Cancer. *J Clin Oncol* 2001; 19:3960-6.
63. Mollna R, Filella X, Torres MD, Bailesta AM, Menguai P, Cases A, et al. SCC Antigen Measured in Malignant and Nonmalignant Diseases. *Clin Chem* 1990;36:251-4
 64. Morice P, Deyrolle C, Rey A, Atallah D, Pautier P, Camatte S, et al. Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery–radiation therapy. *Annals of Oncology* 2004;15: 218–23